Asthma Medication Could Unlock New Cancer Treatments
A new study has revealed that Montelukast, a drug commonly prescribed for asthma and allergies, may hold the key to tackling some of the most difficult cancers, including triple-negative breast cancer.
Researchers discovered that tumors exploit a protein called CysLTR1 to manipulate immune cells known as neutrophils. Normally, neutrophils attack cancer cells and support the immune system. However, in certain cancers, these cells are hijacked to protect tumors and resist immunotherapy.
Montelukast, which blocks CysLTR1, could potentially reprogram neutrophils to regain their cancer-fighting abilities. This breakthrough suggests that an existing, widely available drug might be repurposed to enhance the effectiveness of immunotherapy, a treatment that directs the immune system to target cancer cells.
The findings, published in Nature Cancer on May 19, 2026, were led by Dr. Bin Zhang, professor of cancer immunology at Northwestern University Feinberg School of Medicine. He explained that Montelukast could “revive or reprogram neutrophils to become immune stimulatory cells that sensitize tumors to immunotherapy.”
This discovery is particularly significant for patients with triple-negative breast cancer, a form that lacks targeted therapies and often resists treatment. By combining Montelukast with existing immunotherapies, doctors may soon have a new strategy to treat cancers that previously had limited options.
While the research is still in its early stages, the fact that Montelukast is already approved for asthma means it could move more quickly into cancer trials. If successful, this repurposing could provide a cost-effective and widely accessible treatment option.
For patients in Pakistan and worldwide, this breakthrough offers new hope. With cancer rates rising and treatment options often limited, the possibility of using a familiar asthma drug to fight aggressive cancers could transform healthcare outcomes in the near future.
Leave a Reply